

DMD # 79483

Organic anion transporting polypeptide 1a4 is responsible for the hepatic uptake of cardiac glycosides in mice

Junichi Takano, Kazuya Maeda, Hiroyuki Kusuhashi and Yuichi Sugiyama

Kyorin Pharmaceutical Co., LTD, Tokyo, Japan (J. T.)

Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (K. M.
and H. K.)

Sugiyama Laboratory, RIKEN Innovation Center, RIKEN Cluster for Industry Partnerships,
RIKEN, Yokohama, Japan (Y. S.)

DMD # 79483

Running title: Oatp1a4-mediated hepatic uptake of cardiac glycosides

Corresponding Author:

Junichi Takano

Watarase research center Kyorin Pharmaceutical Co., LTD.

1848, Nogi, Nogi-machi, Shimotsuga-gun, Tochigi-ken, 329-0114, Japan

Tel: +81-280-57-1551, Fax: +81-280-57-2336,

E-mail: junichi.takano@mb.kyorin-pharm.co.jp

Document Statistics:

Text pages: 22

Number of tables: 4

Number of figures: 2

Number of references: 32

Number of words in abstract: 227

Number of words in introduction: 509

Number of words in discussion: 1499

Abbreviations:

BQ-123, cyclo-D-Trp-D-Asp-Pro-D-Val-Leu; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; HPLC, high performance liquid chromatography; LC-MS/MS, liquid chromatography coupled to tandem mass spectrometry; MRM, multiple reaction monitoring; Oatp/OATP, organic anion transporting polypeptide; PCR, polymerase chain reaction; Slco, solute carrier organic anion transporter family

DMD # 79483

Abstract:

Among organic anion transporting polypeptide (Oatp) family transporters expressed in the rodent liver, such as Oatp1a1, Oatp1a4, Oatp1b2, and Oatp2b1, Oatp1a4 has a unique character to recognize neutral cardiac glycosides as substrate in addition to organic anions. The relative contribution of Oatp1a4 to the substrate uptake into hepatocytes has not been clarified. In this study, we investigated the importance of Oatp1a4 in the hepatic uptake of its substrate drugs using *Slco1a4*^{-/-} mice. The hepatic mRNA expression of *Slco1a4* was decreased significantly in *Slco1a4*^{-/-} mice, whereas no differences were seen in other hepatic transporters between wild-type and *Slco1a4*^{-/-} mice. We determined the plasma concentrations, and liver-to-plasma ratio of Oatp1a4 substrates including ouabain, digoxin, BQ-123, fexofenadine, rosuvastatin, pravastatin, nafcillin, and telmisartan, after continuous intravenous infusion. The plasma concentrations of ouabain and rosuvastatin were 2.1 and 1.7-fold higher in *Slco1a4*^{-/-} mice, and the liver-to-plasma concentration ratios of ouabain and digoxin were 13.4 and 4.3-fold lower in *Slco1a4*^{-/-} mice, respectively. Furthermore, the biliary clearance of ouabain and digoxin with regard to plasma concentration were 21.9 and 4.1-fold lower in *Slco1a4*^{-/-} mice, respectively, accompanied with a marked reduction in their liver-to-plasma ratios, whereas the systemic clearance of ouabain, but not digoxin, was reduced significantly in *Slco1a4*^{-/-} mice. These results suggest that Oatp1a4 plays a major role in the hepatic accumulation of cardiac glycosides in mice.

DMD # 79483

Introduction

Transporters, expressed in several tissues, including liver and kidney, are important proteins governing the pharmacokinetics of many drugs. Transporter-mediated uptake from the portal vein into hepatocytes is the first step in their hepatic elimination. Thus, the changes in hepatic uptake clearance can directly affect overall intrinsic hepatic clearance. Organic anion transporting polypeptide (Oatp) family transporters are involved in the efficient uptake of several organic anions into the liver. In rodents, multiple Oatp isoforms such as Oatp1a1, 1a4, 1b2, and 2b1 are expressed on the sinusoidal membrane in hepatocytes (Cheng *et al.*, 2005). Among them, Oatp1a4 encoded by *Slco1a4* (solute carrier organic anion transporter family, member 1a4) is predominantly expressed in the liver and brain. A number of studies for Oatp1a4 in vitro have demonstrated that it accepts not only anionic compounds, such as HMG-CoA reductase inhibitors (pitavastatin, pravastatin, and rosuvastatin), and β -lactam antibiotics (nafcillin, cefmetazole, and cefazolin), but also neutral cardiac glycosides (digoxin and ouabain) and zwitterionic compounds such as fexofenadine (Noé *et al.*, 1997; Cvetkovic *et al.*, 1999; Reichel *et al.*, 1999; Tokui *et al.*, 1999; Ho *et al.*, 2006; Nakakariya *et al.*, 2008; Ose *et al.*, 2010). Oatp1a4 has at least two recognition sites, one for digoxin (neutral compound) and taurocholate (organic anion), and the other for estradiol-17 β -D-glucuronide (Sugiyama *et al.*, 2002). In particular, among rodent Oatp family transporters, digoxin is selectively recognized by Oatp1a4 (Noé *et al.*, 1997; Reichel *et al.*, 1999; Cattori *et al.*, 2000, 2001). Several groups have generated knockout mice for Oatp isoforms and investigated their roles in the hepatic uptake and subsequent pharmacokinetics of substrates. The $K_{p,liver}$ of pravastatin decreased

DMD # 79483

significantly in *Slco1b2*^{-/-} mice (Chen *et al.*, 2008; Zaher *et al.*, 2008). Gong *et al.* reported that the plasma area under the curve of the concentration–time profile (AUC) of estradiol-17β-D-glucuronide was 55% larger in female *Slco1a1*^{-/-} mice than that in wild-type mice, with a 50% reduction in K_{p,liver}; however, knockout of *Slco1a4* did not affect the plasma AUC or K_{p,liver} of estradiol-17β-D-glucuronide, while the plasma AUC of dibromosulfophthalein was 3-fold higher in both *Slco1a1*^{-/-} and *Slco1a4*^{-/-} mice compared with that in wild-type mice (Gong *et al.*, 2011). Moreover, several studies have reported that the changes in pharmacokinetics and tissue distribution of pravastatin, atorvastatin, simvastatin, rosuvastatin, and carboxydichlorofluorescein in Oatp1a/1b cluster knockout mice showed a significant reduction of hepatic uptake because of the lack of major hepatic Oatp isoforms (Iusuf *et al.*, 2012, 2013; Higgins *et al.*, 2014). However, to date, the quantitative contribution of Oatp1a4 to the drug disposition and subsequent pharmacokinetics of substrate drugs in rodents has not been clarified. Ose *et al.* demonstrated that the brain-to-blood transport of pitavastatin, rosuvastatin, pravastatin, and taurocholate after microinjection into the cerebral cortex was decreased significantly in *Slco1a4*^{-/-} mice compared with wild-type mice (Ose *et al.*, 2010). The purpose of the present study was to evaluate the significant involvement of Oatp1a4 in the hepatic uptake in mice of substrate drugs, including digoxin (a selective substrate for Oatp1a4 among Oatp family transporters), with the use of *Slco1a4*^{-/-} mice.

DMD # 79483

Materials and Methods

Chemicals

Ouabain, digoxin, BQ-123, rosuvastatin calcium salt, pravastatin sodium salt, and nafcillin sodium salt were purchased from Wako Pure Chemical Industries (Osaka, Japan). Fexofenadine hydrochloride was purchased from Sigma-Aldrich (St. Louis, MO). Telmisartan was purchased from Tokyo Chemical Industry Co. (Tokyo, Japan). All other chemicals were commercially available, of reagent grade, and used without further purification.

Animals

Slco1a4 knockout (*Slco1a4*^{-/-}) mice were obtained from Deltagen (San Carlos, CA) and maintained by Charles River Laboratories (Yokohama, Japan). *Slco1a4*^{-/-} mice were fertile and exhibited no obvious abnormalities. Wild-type (C57BL/6J) mice were supplied by Oriental Yeast Co. (Tokyo, Japan). All animal experiments were performed with female mice. All mice (10–12 weeks old) were maintained under standard conditions with a reverse dark–light cycle. Food and water were available *ad libitum*. All animal experiments in the present study were performed according to the guidelines provided by the Institutional Animal Care Committee of the Graduate School of Pharmaceutical Sciences, The University of Tokyo (Tokyo, Japan).

Quantification of mRNA expression of various transporters in the murine liver

The mRNA levels of *Slco1a1*, *Slco1a4*, *Slco1b2*, *Slco2b1*, *Abcc2*, *Abcc3*, *Abcb1a*, *Abcg2*,

DMD # 79483

Abcb11, and glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) were quantified by real-time polymerase chain reaction (PCR). Total RNA was isolated from the liver excised from each of four mice using an RNeasy Mini Kit (QIAGEN, Hilden, Germany). Real-time PCR was performed using a Thunderbird SYBR qPCR Mix (Toyobo, Osaka, Japan) and an Applied Biosystems 7500 Fast Real-Time PCR system (Thermo Fisher Scientific, Waltham, MA). An external standard curve was generated by dilution of the mouse liver total RNA (Agilent Technologies, Santa Clara, CA).

In vivo infusion study

Female wild-type and *Sico1a4*^{-/-} mice weighing 17.1 to 29.5 g were used for these experiments. Under pentobarbital anesthesia (30 mg/kg), the jugular vein was cannulated with a polyethylene catheter PE10 (Becton, Dickinson and Company, Franklin Lakes, NJ) for drug administration. The mice received a constant intravenous infusion of ouabain (4.8 µg/hr), digoxin (125 ng/hr), BQ-123 (80 µg/hr), fexofenadine (7.0 µg/hr), rosuvastatin (1.15 µg/hr), pravastatin (8.0 µg/hr), nafcillin (34.3 µg/hr) or telmisartan (480 ng/hr) for 30 min (BQ-123), 60 min (ouabain), and 120 min (digoxin, fexofenadine, rosuvastatin, pravastatin, nafcillin, and telmisartan). Blood samples were collected from the jugular vein, and plasma samples were obtained by centrifugation of the blood samples (10,000g, 10 min, 4°C). The bile duct was cannulated with a polyethylene catheter UT-03 (Unique Medical, Tokyo, Japan) for the bile collection to evaluate the biliary excretion of ouabain and digoxin. The mice were humanely killed after constant infusion, and the entire liver was resected immediately. The liver was weighed and minced, and then mixed with 4-fold volume of

DMD # 79483

PBS. The mixture was homogenized using a polytron homogenizer (Kinematica, Lucerne, Switzerland) in an ice bath. The liver homogenate was centrifuged at 12,000g for 10 min at 4°C. The plasma and liver concentrations of ouabain, digoxin, fexofenadine, rosuvastatin, pravastatin, nafcillin, and telmisartan were determined using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) analysis.

LC-MS/MS analysis

A LC-MS/MS system comprising an Alliance 2695 separation module (Waters, Milford, MA) equipped with a Quattro Micro API tandem mass spectrometer was used for the analysis of ouabain, digoxin, fexofenadine, rosuvastatin, pravastatin, nafcillin, and telmisartan. The mass spectrometer was operated in a positive- and negative-ion electrospray ionization and multiple reaction monitoring (MRM) mode to detect eluting compounds. Ouabain, fexofenadine, and telmisartan were detected as $[M+H]^+$. Rosuvastatin, pravastatin, and nafcillin were detected as $[M-H]^-$. Digoxin was detected as $[M+NH_4]^+$. The MRM transitions of ouabain, digoxin, fexofenadine, rosuvastatin, pravastatin, nafcillin, and telmisartan were m/z 585, 798/651, 502/466, 480/418, 423/321, 333/192 and 515/276, respectively. The collected supernatants were diluted with mobile phase. The diluted samples (10 μ L) were injected into the LC-MS/MS system. Samples containing ouabain, digoxin, fexofenadine, rosuvastatin, pravastatin, nafcillin samples were separated on an Atlantis T3 column (2.1 \times 50 mm, 5 μ m, Waters), and for telmisartan, a Inertsil ODS-3 column (2.1 \times 50 mm, 5 μ m, GL Sciences) was used. The details of the high performance liquid chromatography (HPLC) conditions are shown in Table 1.

DMD # 79483

HPLC-fluorescence analysis

An HPLC-fluorescence system was used to analyze BQ-123. A diluted sample (100 μ L) was injected into an HPLC system using a YMC-Pack ODS-A column (4.6 \times 150 mm, 5 μ m, YMC Co.). The column was eluted with water–acetonitrile (65:35, v/v) containing 0.1% trifluoroacetic acid at 0.8 mL/min. BQ-123 was detected by fluorescence (excitation 287 nm, emission 348 nm).

Pharmacokinetic analysis

Total clearance (CL_{tot}), biliary excretion clearance with regard to plasma concentration ($CL_{bile,plasma}$), and biliary excretion clearance with regard to liver concentration ($CL_{bile,liver}$) were calculated using the following equations:

$$CL_{tot} = \text{Infusion rate}/C_{p,ss} \quad (1)$$

$$CL_{bile, plasma} = V_{bile}/C_{p,ss} \quad (2)$$

$$CL_{bile, liver} = V_{bile}/C_{liver,ss} \quad (3)$$

where $C_{p,ss}$, $V_{bile,ss}$, and $C_{liver,ss}$ represent the plasma concentration, biliary excretion rate, and liver concentration at steady state, respectively. In the present study, $C_{p,ss}$ and $C_{liver,ss}$ were defined as the plasma and liver concentrations of the parent compounds at 30 min (BQ-123), 60 min (ouabain), or 120 min (digoxin, fexofenadine, rosuvastatin, pravastatin, nafcillin, and telmisartan), judging from their time courses of plasma concentration. $V_{bile,ss}$ was calculated as the biliary excretion rate of ouabain and digoxin from 40 to 60 min and from 90 to 120 min, respectively. To calculate $C_{liver,ss}$, the specific gravity of the liver was

DMD # 79483

assumed to be 1. Thus, the amount of compound in one gram of liver (ng/g) can be regarded as its liver concentration (ng/mL).

Statistical analysis

The means and standard deviations of mRNA expression level, drug concentration in the plasma and liver, and pharmacokinetic parameters were calculated for both wild-type and *Slco1a4*^{-/-} mice. A Student two-tailed unpaired *t* test was used to identify significant differences. *P* < 0.05 was considered significant.

DMD # 79483

Results

Analysis of mRNA expression levels of hepatic transporters in wild-type and *Slco1a4*^{-/-} mice

The mRNA expression levels of hepatic transporters in wild-type and *Slco1a4*^{-/-} mice are compared in Table 2. As expected, *Slco1a4* mRNA showed a significantly lower expression in *Slco1a4*^{-/-} mice, but no significant difference was observed in mRNA expression levels of other tested hepatic transporters between wild-type and *Slco1a4*^{-/-} mice.

Time profiles for plasma concentrations of substrate drugs in wild-type and *Slco1a4*^{-/-} mice after constant intravenous infusion

The plasma concentrations of ouabain, digoxin, BQ-123, fexofenadine, rosuvastatin, pravastatin, nafcillin, and telmisartan after constant intravenous infusion into wild-type and *Slco1a4*^{-/-} mice are shown in Fig. 1 and Table 3. The plasma concentrations of ouabain and rosuvastatin at steady state were significantly increased in *Slco1a4*^{-/-} mice, whereas the plasma concentrations of pravastatin and telmisartan were slightly decreased in *Slco1a4*^{-/-} mice. The plasma concentrations of other substrates were not different between wild-type and *Slco1a4*^{-/-} mice. The total clearance calculated by the ratio of infusion rate to C_{p,ss} (CL_{tot}) in wild-type and *Slco1a4*^{-/-} mice is shown in Fig. 2. The CL_{tot} of ouabain and rosuvastatin was decreased significantly in *Slco1a4*^{-/-} mice, whereas that of other substrates were not different between wild-type and *Slco1a4*^{-/-} mice. The liver concentrations and liver-to-plasma concentration ratio (K_{p,liver}) of substrate drugs at steady

DMD # 79483

state in wild-type and *Slco1a4*^{-/-} mice are shown in Table 3. The liver concentrations and $K_{p,liver}$ of ouabain and digoxin were decreased significantly in *Slco1a4*^{-/-} mice. By contrast, the $K_{p,liver}$ of telmisartan was significantly increased in *Slco1a4*^{-/-} mice. The liver concentrations and $K_{p,liver}$ of other substrates were not different between wild-type and *Slco1a4*^{-/-} mice.

Pharmacokinetic parameters of ouabain and digoxin after constant intravenous infusion into wild-type and *Slco1a4*^{-/-} mice

The pharmacokinetic parameters of ouabain and digoxin in wild-type and *Slco1a4*^{-/-} mice are shown in Table 4. Comparing the pharmacokinetic parameters between wild-type and *Slco1a4*^{-/-} mice, the CL_{tot} of ouabain in *Slco1a4*^{-/-} mice decreased significantly, while that of digoxin decreased slightly. Furthermore, after constant intravenous infusion of ouabain and digoxin, both the biliary excretion rate at steady state (V_{bile}) and the biliary excretion clearance with regard to the plasma concentration ($CL_{bile, plasma}$) were decreased in *Slco1a4*^{-/-} mice. However, the biliary excretion clearance with regard to the hepatic concentration ($CL_{bile, liver}$) of ouabain and digoxin showed no difference between wild-type and *Slco1a4*^{-/-} mice.

DMD # 79483

Discussion

To elucidate the role of Oatp1a4 in the hepatic uptake of substrate drugs, we determined the hepatic clearance and distribution of Oatp1a4 substrates using *Slco1a4*^{-/-} mice. According to the previous report (Cheng *et al.*, 2005), mRNA expression level of Oatp1a4 in the liver was significantly higher in female than male. Thus, to sensitively characterize the importance of Oatp1a4-mediated transport, we decided to use female mice in the current study. We found that the $K_{p,liver}$ of ouabain and digoxin were decreased significantly in *Slco1a4*^{-/-} mice. In experiments using *Xenopus* oocytes expressing rodent Oatp transporters, digoxin was found to be transported selectively via Oatp1a4 (Noé *et al.*, 1997; Reichel *et al.*, 1999; Cattori *et al.*, 2000, 2001). By contrast, ouabain was recognized by Oatp1a1 and Oatp1a4 with higher affinity to Oatp1a4 (Oatp1a1; $K_m = 1700\text{--}3000\text{ }\mu\text{M}$, Oatp1a4; $K_m = 470\text{ }\mu\text{M}$ (Bossuyt *et al.*, 1996; Eckhardt *et al.*, 1999; Noé *et al.*, 1997)). The observed decrease of $K_{p,liver}$ of these compounds in *Slco1a4*^{-/-} mice can be explained by the relatively higher contribution of Oatp1a4 to their overall uptake. By contrast, the identical uptake of digoxin by primary cultured hepatocytes isolated from wild-type and *Slco1a4*^{-/-} mice was reported (Gong *et al.*, 2011). This apparent discrepancy can be explained, at least in part, by the high affinity of digoxin for rat Oatp1a4 ($K_m = 0.24\text{ }\mu\text{M}$). In the previous in vitro study, 1 μM of digoxin was used in the incubation medium, which may partially saturate Oatp1a4-mediated transport. Conversely, in our study, the plasma unbound concentration of digoxin was far below its K_m ; therefore, Oatp1a4-mediated hepatic uptake was expected to be clearly observed. The CL_{tot} of ouabain in *Slco1a4*^{-/-} mice decreased significantly, but that of digoxin decreased only slightly. The CL_{tot} of ouabain and digoxin is

DMD # 79483

much lower than the liver blood flow rate in mice (90 mL/min/kg), so the hepatic clearance of ouabain and digoxin should approximate $f_B \times CL_{H,int}$. Based on the extended clearance concept, overall intrinsic hepatic clearance ($CL_{H,int}$) consists of multiple intrinsic processes, such as hepatic influx (PS_{inf}), backflux from cells to blood (PS_{eff}), metabolism (CL_{met}), and biliary excretion in an unchanged form (CL_{bile}). Then, $CL_{H,int}$ and $K_{p,liver}$ can be described theoretically by the following equations:

$$CL_{H,int} = PS_{inf} \times \frac{CL_{bile} + CL_{met}}{PS_{eff} + CL_{bile} + CL_{met}} \quad (4)$$

$$K_{p,liver} = \frac{f_B}{f_T} \times \frac{PS_{inf}}{PS_{eff} + CL_{bile} + CL_{met}} \quad (5)$$

where f_B and f_T represent the protein unbound fraction in blood and tissue, respectively.

Based on these equations, the decrease in the transport activity of Oatp1a4-mediated hepatic uptake results in a decrease in PS_{inf} , and subsequently, $CL_{H,int}$ and $K_{p,liver}$ should be decreased. Actually, the $K_{p,liver}$ of ouabain and digoxin were decreased in *Slco1a4*^{-/-} mice, whereas no differences were observed in the $CL_{bile,liver}$ between wild-type and *Slco1a4*^{-/-} mice. The extent of decrease in $K_{p,liver}$ of ouabain and digoxin in *Slco1a4*^{-/-} mice (92.6% and 76.9% decrease, respectively) was similar to that of $CL_{bile,plasma}$ in *Slco1a4*^{-/-} mice (95.4% and 75.7% decrease, respectively). Hence, decreases in $K_{p,liver}$ can be explained by functional deficiency of Oatp1a4-mediated hepatic uptake. On the other hand, the CL_{tot} of ouabain in *Slco1a4*^{-/-} mice decreased significantly to 45.8% of wild-type mice, whereas that of digoxin slightly decreased to 76.7% (Table 4). The change in CL_{tot} in *Slco1a4*^{-/-} mice depends on the relative contribution of CL_H to CL_{tot} in wild-type mice. The $K_{p,liver}$ of ouabain in *Slco1a4*^{-/-} was decreased to 7.4% of that in wild-type. If PS_{eff} , CL_{bile} , and CL_{met}

DMD # 79483

between wild-type and *Slco1a4*^{-/-} mice were not changed, CL_H of ouabain in *Slco1a4*^{-/-} mice was decreased to 7.4% on the basis of equations (4) and (5). Thus, the relative contribution of CL_H to CL_{tot}, which can quantitatively explain the observed CL_{tot} change (46% of wild-type) in *Slco1a4*^{-/-} mice, should be calculated as 58.5% in wild-type mice (58.5*0.074+41=45.8). In the case of digoxin, its CL_H in *Slco1a4*^{-/-} mice was calculated to be decreased to 23.1%. Thus, the change in the CL_{tot} of digoxin can be explained if CL_H is 30% of CL_{tot} in wild-type mice. In actual, the relative CL_{bile,plasma} to CL_{tot} of ouabain was 28% in wild-type mice, which was higher than that of digoxin (9%). Considering low metabolic clearance of digoxin in mice (Kawahara *et al.*, 1999), a hepatic elimination is more important for ouabain than digoxin. According to the previous reports, the relative contribution of CL_H to CL_{tot} of digoxin was 44.2% in C57BL/6 mice (Kawahara *et al.*, 1999), while that of ouabain was more than 74% in rats, although no data were available for mice (Meijer and van Monffoort, 2002). In addition, the urinary recovery of ouabain in humans was 37% (Selden and Smith, 1972), whereas 80% of digoxin was excreted into urine in an unchanged form (Aronson, 1980). These results suggest that more digoxin than ouabain tends to be excreted into the urine. Calculating the glomerular filtration clearance of unbound drug (fu*GFR) for ouabain and digoxin in mouse, those of ouabain and digoxin are 13.3 and 10.9 mL/min; where fu for ouabain and digoxin, and GFR are 0.95 (rat), 0.78 (mouse) and 14 mL/min/kg (Davies and Morris, 1993; Kawahara *et al.*, 1999; Meijer and van Monffoort, 2002). Those were similar to the CL_{tot} of ouabain and digoxin in *Slco1a4*^{-/-} mice, respectively. Therefore, the different change in the CL_{tot} of ouabain and digoxin can be explained rationally by the different contribution of hepatic elimination to total clearance.

DMD # 79483

Considering the hepatic uptake transporters in human, digoxin was selectively recognized by OATP1B3 despite only 43% amino acid sequence identity with mouse Oatp1a4 (Kullak-Ublick *et al.*, 2001). By contrast, Taub *et al.* reported that digoxin was not a substrate of OATP1A2, OATP1B1, OATP1B3, and OATP2B1 in in vitro experiments (Taub *et al.*, 2011). In human hepatocytes, uptake of digoxin was partly mediated by saturable carrier(s), though no hepatic OATPs can transport digoxin (Kimoto *et al.*, 2011). Ouabain was recognized by OATP1B3 and OATP1A2 (Kullak-Ublick *et al.*, 2001). Though OATP1A2 shows the highest identity with mouse Oatp1a4 (73%) among human OATP isoforms, its protein expression was very low in human liver (Wegler *et al.*, 2017) and mainly expressed in cholangiocytes (Lee *et al.*, 2005). Therefore, the species differences in transporter-mediated uptake of cardiac glycosides between humans and rodents need to be carefully discussed due to a lack of genetic and functional correspondence.

The plasma concentration of rosuvastatin was increased significantly in *Slco1a4*^{-/-} mice, and its $K_{p,liver}$ was decreased slightly. The $K_{p,liver}$ of rosuvastatin was decreased by approximately 50% in *Slco1b2*^{-/-} mice (DeGorter *et al.*, 2012). Moreover, $K_{p,liver}$ of rosuvastatin after intravenous administration was reduced 5- to 10-fold in Oatp1a/1b cluster knockout mice (Iusuf *et al.*, 2013). This reduction suggested that the hepatic uptake of rosuvastatin is mediated by Oatp1a/1b transporters including Oatp1b2, with a minor contribution of Oatp1a4.

By contrast, the $K_{p,liver}$ of BQ-123, fexofenadine, pravastatin, and nafcillin were not different between wild-type and *Slco1a4*^{-/-} mice. BQ-123, fexofenadine, and nafcillin are transported via multiple Oatp isoforms, Oatp1a1 and Oatp1b2, in addition to Oatp1a4

DMD # 79483

(Cvetkovic *et al.*, 1999; Reichel *et al.*, 1999; Cattori *et al.*, 2001; Ho *et al.*, 2006; Nakakariya *et al.*, 2008). No differences in their $K_{p,liver}$ were observed between wild-type and *Slco1a4*^{-/-} mice, which suggests that contribution of Oatp1a4 to their hepatic uptake is not dominant. Pravastatin can be transported by Oatp1a1, Oatp1a4, and Oatp1b2 (Hsiang *et al.*, 1999; Tokui *et al.*, 1999; Sasaki *et al.*, 2004). The $K_{p,liver}$ of pravastatin was reduced 3-fold in *Slco1b2*^{-/-} mice (Zaher *et al.*, 2008) and 10- to 200-fold in Oatp1a/1b cluster knockout mice (Iusuf *et al.*, 2012; Higgins *et al.*, 2014). These results suggest that Oatp1a/1b transporters, at least Oatp1b2, contribute to the hepatic uptake of pravastatin. About 90% of nafcillin uptake into isolated rat hepatocytes is mediated by Oatp1a4 based on a relative activity factor method (Nakakariya *et al.*, 2008). Although the exact reason for that discrepancy is unknown, it might be the result of species difference in the relative contribution of Oatp isoforms.

Unexpectedly, we found that the $K_{p,liver}$ of telmisartan was significantly increased in *Slco1a4*^{-/-} mice. The uptake of telmisartan in isolated rat hepatocytes is inhibited by digoxin in a concentration-dependent manner (Ishiguro *et al.*, 2006). Oatp1a4-mediated transport is completely inhibited by 100 μ M digoxin in rats, whereas Oatp1a1-mediated transport is not (Sugiyama *et al.*, 2002). Therefore, rat Oatp1a4 is considered to be partly involved in the hepatic uptake of telmisartan. Although the exact mechanism remains unknown, it is implied that hepatic influx clearance mediated by other transporters is increased and/or that the hepatic efflux clearance and metabolic clearance of telmisartan is decreased by knocking out the *Slco1a4* gene, even though the mRNA expression levels of several typical hepatic transporters are unchanged in *Slco1a4*^{-/-} mice.

DMD # 79483

In conclusion, we clarified that the hepatic distribution of ouabain and digoxin is dominated by Oatp1a4 in mice, and that systemic clearance of ouabain is significantly reduced in *S/co1a4^{-/-}* mice because of the large contribution of its hepatic elimination. These findings suggest that Oatp1a4 plays an important role in the hepatic uptake of neutral cardiac glycosides in mice.

DMD # 79483

Author Contributions

Wrote Manuscript: Takano, Maeda, Kusuhara and Sugiyama

Designed Research: Takano, Maeda, Kusuhara and Sugiyama

Performed Research: Takano, Maeda and Sugiyama

Analyzed Data: Takano, Maeda and Sugiyama

Contributed New Reagents/Analytical Tools: Takano and Maeda

DMD # 79483

References

- Aronson JK (1980) Clinical pharmacokinetics of digoxin 1980. *Clin Pharmacokinet* **5**:137–149.
- Bossuyt X, Müller M, Hagenbuch B, and Meier PJ (1996) Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. *J Pharmacol Exp Ther* **276**:891–896.
- Cattori V, Hagenbuch B, Hagenbuch N, Stieger B, Ha R, Winterhalter KE, and Meier PJ (2000) Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver. *FEBS Lett* **474**:242–245.
- Cattori V, van Montfoort JE, Stieger B, Landmann L, Meijer DK, Winterhalter KH, Meier PJ, and Hagenbuch B (2001) Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. *Pflügers Arch* **443**:188–195.
- Chen C, Stock JL, Liu X, Shi J, Van Deusen JW, DiMattia DA, Dullea RG, and de Morais SM (2008) Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds. *Drug Metab Dispos* **36**:1840–1845.
- Cheng X, Maher J, Chen C, and Klaassen CD (2005) Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). *Drug Metab Dispos* **33**:1062–1073.
- Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. *Drug Metab Dispos* **27**:866–871.
- Davies B, and Morris T (1993) Physiological parameters in laboratory animals and humans. *Pharm Res* **10**:1093–1095.
- DeGorter MK, Urquhart BL, Gradhand U, Tirona RG, and Kim RB (2012) Disposition of Atorvastatin, Rosuvastatin, and Simvastatin in Oatp1b2^{-/-} Mice and Intraindividual Variability in Human Subjects. *J Clin Pharmacol* **52**:1689–1697.
- Eckhardt U, Schroeder A, Stieger B, Höchli M, Landmann L, Tynes R, Meier PJ, and Hagenbuch B (1999) Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in

DMD # 79483

- stably transfected CHO cells. *Am J Physiol* **276**:1037–1042.
- Gong L, Aranibar N, Han Y-H, Zhang Y, Lecureux L, Bhaskaran V, Khandelwal P, Klaassen CD, and Lehman-McKeeman LD (2011) Characterization of organic anion-transporting polypeptide (Oatp) 1a1 and 1a4 null mice reveals altered transport function and urinary metabolomic profiles. *Toxicol Sci* **122**:587–597.
- Higgins JW, Bao JQ, Ke AB, Manro JR, Fallon JK, Smith PC, and Zamek-Gliszczynski MIJ (2014) Utility of oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: Case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. *Drug Metab Dispos* **42**:182–192.
- Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang YI, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. *Gastroenterology* **130**:1793–1806.
- Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, and Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. *J Biol Chem* **274**:37161–37168.
- Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, and Sugiyama Y (2006) Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. *Drug Metab Dispos* **34**:1109–1115.
- Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy KE, van de Steeg E, Wagenaar E, Beijnen JH, and Schinkel AH (2012) Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. *Mol Pharm* **9**:2497–2504.
- Iusuf D, van Esch A, Hobbs M, Taylor M, Kenworthy KE, van de Steeg E, Wagenaar E, and Schinkel AH (2013) Murine Oatp1a/1b Uptake Transporters Control Rosuvastatin Systemic Exposure Without Affecting Its Apparent Liver Exposure. *Mol Pharmacol* **83**:919–929.

DMD # 79483

- Kawahara M, Sakata A, Miyashita T, Tamai I, and Tsuji A (1999) Physiologically based pharmacokinetics of digoxin in *mdr1a* knockout mice. *J Pharm Sci* **88**:1281–1287.
- Kimoto E, Chupka J, Xiao Y, Bi YA, and Duignan DB (2011) Characterization of digoxin uptake in sandwich-cultured human hepatocytes. *Drug Metab Dispos* **39**:47–53.
- Kullak-Ublick GA, Ismail MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, and Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. *Gastroenterology* **120**:525–533.
- Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, and Kim RB (2005) Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): Implications for altered drug disposition and central nervous system drug entry. *J Biol Chem* **280**:9610–9617.
- Meijer DKF, and van Montfort JE (2002) Interactions of cationic drugs and cardiac glycosides at the hepatic uptake level: studies in the rat in vivo, isolated perfused rat liver, isolated rat hepatocytes and oocytes expressing *oatp2*. *Arch Pharm Res* **25**:397–415.
- Nakakariya M, Shimada T, Irokawa M, Koibuchi H, Iwanaga T, Yabuuchi H, Maeda T, and Tamai I (2008) Predominant contribution of rat organic anion transporting polypeptide-2 (*Oatp2*) to hepatic uptake of beta-lactam antibiotics. *Pharm Res* **25**:578–585.
- Noé B, Hagenbuch B, Stieger B, and Meier PJ (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. *Proc Natl Acad Sci U S A* **94**:10346–10350.
- Ose A, Kusuhara H, Endo C, Tohyama K, Miyajima M, Kitamura S, and Sugiyama Y (2010) Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. *Drug Metab Dispos* **38**:168–176.
- Reichel C, Gao B, Van Montfort J, Cattori V, Rahner C, Hagenbuch B, Stieger B, Kamisako T, and Meier PJ (1999) Localization and function of the organic anion-transporting polypeptide *Oatp2* in rat liver. *Gastroenterology* **117**:688–695.

DMD # 79483

Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, and Sugiyama Y (2004) Prediction of in Vivo Biliary Clearance from the in Vitro Transcellular Transport of Organic Anions across a Double-Transfected Madin-Darby Canine Kidney II Monolayer Expressing Both Rat Organic Anion Transporting Polypeptide 4 and Multidrug Resistance As. *Mol Pharmacol* **66**:450–459.

Selden R, and Smith TW (1972) Ouabain pharmacokinetics in dog and man. Determination by radioimmunoassay. *Circulation* **45**:1176–1182.

Sugiyama D, Kusuhara H, Shitara Y, Abe T, and Sugiyama Y (2002) Effect of 17 beta-estradiol-D-17 beta-glucuronide on the rat organic anion transporting polypeptide 2-mediated transport differs depending on substrates. *Drug Metab Dispos* **30**:220–223.

Taub ME, Mease K, Sane RS, Watson CA, Chen L, Ellens H, Hirakawa B, Reyner EL, Jani M, and Lee CA (2011) Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells. *Drug Metab Dispos* **39**:2093–2102.

Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, and Sugiyama Y (1999) Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. *Pharm Res* **16**:904–908.

Wegler C, Gaugaz FZ, Andersson TB, Wiśniewski JR, Busch D, Gröer C, Oswald S, Norén A, Weiss F, Hammer HS, Joos TO, Poetz O, Achour B, Rostami-Hodjegan A, Van De Steeg E, Wortelboer HM, and Artursson P (2017) Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes. *Mol Pharm* **14**:3142–3151.

Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, Palandra J, Stock JL, Kim RB, and Ware JA (2008) Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. *Mol Pharmacol* **74**:320–329.

DMD # 79483

Figure legends

Fig. 1. Time profiles of the plasma concentration of substrate drugs in wild-type and *Slco1a4*^{-/-} mice. The plasma concentrations of ouabain (A), digoxin (B), BQ-123 (C), fexofenadine (D), rosuvastatin (E), pravastatin (F), nafcillin (G), and telmisartan (H) after constant intravenous infusion into wild-type (○) and *Slco1a4*^{-/-} mice (●) are shown. Each point represents the mean ± S.D. (n = 3).

Fig. 2. Total clearance (CL_{tot}) in wild-type and *Slco1a4*^{-/-} mice. CL_{tot} was calculated as the ratio of infusion rate to C_{p,ss}. C_{p,ss} was estimated as the plasma concentration of the parent compounds at 30 min (BQ-123), 60 min (ouabain), or 120 min (digoxin, fexofenadine, rosuvastatin, pravastatin, nafcillin and telmisartan). Each bar represents the mean ± S.D. (n = 3).

Table 1. Analytical conditions for HPLC

Compound	Mobile phase		Gradient condition (B concentration %)
	A	B	
Ouabain	5 mM ammonium formate	Acetonitrile	1 min, 40%→2 min, 80%→5 min, 80%→5.01 min, 40%→8 min, 40%
Digoxin	10 mM ammonium formate	Acetonitrile	0.5 min, 60%→1 min, 95%→3 min, 95%→3.05 min, 60%→5 min, 60%
Fexofenadine	0.1% Formic acid	Acetonitrile	0.5 min, 18%→1.5 min, 60%→4 min, 60%→4.05 min, 60%→6 min, 18%
Rosuvastatin	0.1% Formic acid	Acetonitrile	1 min, 5%→3 min, 45%→3.5 min, 45%→3.55 min, 5%→6.5 min, 5%
Pravastatin	0.1% Formic acid	Acetonitrile	0.5 min, 25%→1.5 min, 80%→4 min, 80%→4.01 min, 25%→6 min, 25%
Nafcillin	0.1% Formic acid	Acetonitrile	1 min, 15%→2 min, 45%→4 min, 45%→4.1 min, 15%→6 min, 15%
Telmisartan	10 mM ammonium acetate	Methanol	0.5 min, 55%→1.5 min, 80%→4 min, 80%→4.01 min, 25%→6 min, 25%

Table 2. mRNA expression levels of transporters in the mouse liver

	Transporter gene/ <i>Gapdh</i>		Ratio (<i>Slco1a4</i> ^{-/-} /wild-type)
	Wild-type	<i>Slco1a4</i> ^{-/-}	
<i>Slco1a1</i>	0.144 ± 0.084	0.0982 ± 0.0675	0.68
<i>Slco1a4</i>	2.87 ± 0.89	0.0595 ± 0.0386***	0.021
<i>Slco1b2</i>	1.29 ± 0.63	1.53 ± 1.21	1.2
<i>Slco2b1</i>	1.04 ± 0.35	0.982 ± 0.722	0.95
<i>Abcc2</i>	1.31 ± 0.15	1.03 ± 0.35	0.79
<i>Abcc3</i>	0.298 ± 0.133	0.355 ± 0.362	1.2
<i>Abcb1a</i>	4.61 ± 1.68	6.24 ± 5.42	1.4
<i>Abcg2</i>	0.920 ± 0.439	1.34 ± 1.46	1.5
<i>Abcb11</i>	0.473 ± 0.292	0.722 ± 0.518	1.5

Values are normalized by expression of *Gapdh* and expressed as mean ± S.D. (n = 4).

****P* < 0.001

Table 3. $C_{p,ss}$, $C_{liver,ss}$, and $K_{p,liver}$ of substrate drugs in wild-type and *Slco1a4*^{-/-} mice

Compound	$C_{p,ss}$ (ng/mL)		$C_{liver,ss}$ (ng/g liver)		$K_{p,liver}$	
	Wild-type	<i>Slco1a4</i> ^{-/-}	Wild-type	<i>Slco1a4</i> ^{-/-}	Wild-type	<i>Slco1a4</i> ^{-/-}
Ouabain	120 ± 26	256 ± 31**	1270 ± 410	207 ± 145*	10.4 ± 1.3	0.774 ± 0.451***
Digoxin	7.51 ± 3.36	8.76 ± 2.26	55.9 ± 11.6	16.0 ± 2.8**	8.0 ± 2.04	1.86 ± 0.22 *
BQ-123	1410 ± 130	1280 ± 100	4990 ± 420	4450 ± 990	3.5 ± 0.63	3.46 ± 0.60
Fexofenadine	185 ± 11	189 ± 5	2940 ± 450	2750 ± 1150	16.0 ± 3.4	14.6 ± 6.5
Rosuvastatin	15.6 ± 2.3	26.3 ± 5.8*	43.0 ± 14.6	58.0 ± 6.7	2.7 ± 0.57	2.24 ± 0.25
Pravastatin	73.3 ± 11.0	57.6 ± 9.5	434 ± 95	323 ± 140	6.1 ± 2.04	5.73 ± 2.81
Nafcillin	897 ± 361	1050 ± 110	18900 ± 2400	16100 ± 4400	23.6 ± 9.6	15.2 ± 2.8
Telmisartan	26.4 ± 3.6	20.2 ± 1.9	2220 ± 150	2060 ± 430	79.4 ± 14.6	113 ± 8*

$C_{p,ss}$ and $C_{liver,ss}$ were estimated as the plasma and liver concentrations of the parent compounds at 30 min (BQ-123), 60 min (ouabain), or 120 min (digoxin, fexofenadine, rosuvastatin, pravastatin, nafcillin and telmisartan).

* $P < 0.05$

** $P < 0.01$

*** $P < 0.001$

Table 4. Pharmacokinetic parameters of ouabain and digoxin after constant intravenous infusion in wild-type and *Slco1a4*^{-/-} mice

Compounds		CL _{tot} (mL/min/kg)	K _{p,liver}	V _{bile} (ng/min)	CL _{bile,plasma} (mL/min/kg)	CL _{bile,liver} (mL/min/kg)
Ouabain	Wild-type	32.3 ± 6.2	10.4 ± 1.3	22.7 ± 6.7	9.10 ± 3.26	0.916 ± 0.435
	<i>Slco1a4</i> ^{-/-}	14.8 ± 1.9**	0.773 ± 0.451***	2.30 ± 0.91**	0.420 ± 0.164**	0.642 ± 0.408
Digoxin	Wild-type	14.6 ± 6.8	8.05 ± 2.04	0.206 ± 0.100	1.34 ± 0.59	0.165 ± 0.63
	<i>Slco1a4</i> ^{-/-}	11.2 ± 2.0	1.86 ± 0.22*	0.0641 ± 0.0295	0.325 ± 0.089*	0.179 ± 0.064

CL_{tot}: total plasma clearance, K_{p,liver}: liver-to-plasma concentration ratio at steady state, V_{bile}: biliary excretion rate at steady state, CL_{bile,plasma}: biliary excretion clearance with regard to the plasma concentration, CL_{bile,liver}: biliary excretion clearance with regard to the hepatic concentration.

**P* < 0.05


***P* < 0.01

****P* < 0.001


DMD # 79483

Figure 1


A




B




C




D




E



F



G



H




Figure 2

